INFO SHEET

ADC Screening Solutions Using Patient-Derived Organoids

Translating ADC biology into clinical decisions starts with the right preclinical model. Antibody–drug conjugates combine target specificity with potent cytotoxic payloads—yet clinical translation remains challenging. Target antigen expression alone frequently fails to predict response, and conventional in vitro systems can mislead: cell lines often overexpress antigens, while animal models are costly and may not capture the diversity of human tumor biology.

HUB Organoids' ADC screening platform brings patient biology into your decision-making—early. Using patient-derived tumor organoids (PDOs) and patient-matched normal organoids, we support ADC programs from target validation through translational strategy.

A Modular, Patient-Relevant Platform for ADC Development

Our ADC screening solutions are built on a flexible, modular workflow designed to fit your stage and scientific question. The platform integrates:

• OrganoID-Flow: flow cytometry-based quantification of membrane and intracellular target antigen (TAA) expression across PDO panels, aligned with transcriptomics for robust model selection
  
  
• ADC Efficacy and Optimization Screens: potency quantification and therapeutic window assessment across genetically diverse tumor organoids spanning multiple epithelial oncology indications
  
  
• Internalisation and Killing Dynamics Assay: imaging-based real-time tracking of ADC internalisation paired with parallel cytotoxicity readouts to dissect MoA drivers beyond antigen expression
  
  
• Co-clinical Development Support: translating organoid responses into biomarker strategies and patient stratification frameworks for clinical trials

Download Our Brochure to Learn About:

• How patient-derived organoids preserve tumor antigen biology and capture inter-patient variability
  
  
• An overview of HUB Organoids' ADC screening modules, including design, readouts, and indications covered
  
  
• A case study using Tivdak™ (tisotumab vedotin) across 22 tumor organoid models spanning seven indications—and what it revealed about biomarkers of response beyond target expression

FOR RESEARCH USE ONLY. Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

HUB Organoids is now part of the Life Science Business of Merck KGaA, Darmstadt, Germany